Sixteen years ago, in 2006, founding editor Prof. James Jett and the International Association for the Study of Lung Cancer (IASLC) launched the Journal of Thoracic Oncology
The new official journal of the IASLC.
The JTO aimed to provide the IASLC with new opportunities and expand horizons. In 2013, Prof. Jett handed over the editorship to Prof. Alex Adjei. By this time, the JTO was an established, international journal attracting submissions from around the world.
The JTO expanded its remit, aiming for submissions from multiple disciplines and across areas that ranged from genomics to public health.
Now that JTO has come of age, what’s next?.
Under the leadership of Prof. Adjei, the depth and reputation of JTO grew, matched by the rise in impact factor, to rank among the highest-level journals in both pulmonology and oncology. Nearly 3 years ago, just as the coronavirus disease 2019 pandemic began, Prof. Adjei launched JTO Clinical and Research Reports
(JTO CRR), the gold open-access sister to JTO.
The IASLC needed more journal space for the “meritorious manuscripts”
that could just not get in to JTO. Thoracic oncology has changed from a field struggling against “neglect and nihilistic attitudes”
Now that JTO has come of age, what’s next?.
to one of the most rapidly advancing fields in pulmonary medicine, imaging, oncology, pathology, surgery, public health, nursing care, and patient advocacy. The pace of submissions to our journals reflects the speed of this change. For lung cancer clinicians, the IASLC journals have long addressed true, pressing questions that arise in practice every day. The IASLC and the journal editors have provided critical leadership in bringing together extraordinary and talented people to tackle the problems our patients face. The two journals together drive excellence in research, reach across international borders, influence clinical practice, and lead the way in global thoracic oncology.
The IASLC and its journals have uncovered and met a need. Whether you track the JTO impact factor or follow the high-quality and expanding content of both journals, the significant factors are clear. JTO and JTO CRR publish papers that cover all aspects of thoracic oncology, from case studies to phase 3 clinical trials. The journals publish updates on thoracic malignancies from all parts of the world, making specific efforts to capture academic contributions from as many places as possible. Contributing authors come from all disciplines. Papers extend beyond molecularly focused clinical trials to tobacco control and cessation, prevention, screening, novel treatments for early stage disease, clinical public health, and survivorship. The journals publish on practice-changing research into health services and implementation of major programs such as lung cancer screening; the journals work hard to balance the need for efficient and rapid editorial decisions with a commitment to quality.
There are other journals that focus on lung cancer, tobacco control, targeted therapies, translational research, and issues specific to geographic regions. Studies in lung cancer, whether on screening, novel therapies, or developments in surgery, are featured in some of the most eminent journals in the world. So, why the IASLC and why the two journals? The answer is in the society’s mission as the “only global network… [for]…the study and eradication” of thoracic malignancies.
The IASLC and therefore the journals are perfectly positioned to develop worldwide academic platforms. These platforms address the full range of issues that affect people with thoracic malignancies and support those working to improve outcomes. The society started with public health concerns and the wish for collaboration.
This developed through JTO to include prevention, detection, diagnosis, and treatments with a strong focus on translational research. As JTO’s companion journal, JTO CRR provides a publication home within the IASLC for research with a more clinical focus and for article types not generally considered by JTO—case reports, phase 1 and 2 trials, high-impact retrospective studies, and database analyses. In addition, JTO CRR has scope to explore new approaches that may include high-quality debates, public health interventions, graphical abstracts, and online interactive formats.
The IASLC and JTO have grown and matured during a rich and rewarding time for scientists and clinicians working to eradicate lung cancer. Major developments in prevention, screening, early diagnosis, and management of thoracic malignancies have already improved outcomes. The addition of JTO CRR adds breadth to the scholarship supported by IASLC and opens new directions for our scientific community. The JTO CRR has had a sure start with its founding editor Prof. Adjei. I am privileged to take the baton for the next leg of the journey.
CRediT Authorship Contribution Statement
Emily Stone: Writing—original draft, Writing—review and editing.
Published online: December 16, 2022
Publication stageIn Press Journal Pre-Proof
Disclosure: Dr. Stone declares no conflict of interest.
Cite this article as: Stone E. Building on a legacy. JTO Clin Res Rep. XXXX;X:XXXXXX.
© 2022 Published by Elsevier Inc. on behalf of the International Association for the Study of Lung Cancer.